Status: Recruiting
A Phase 1 Study of GTX-B001 in Healthy Subjects and Patients With Chronic Inducible Urticaria
This is a first-in-human study aimed at determining the safety of a single dose of GTX-B001 in healthy participants and in people with chronic inducible urticaria.
Participants needed: 72
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Granular Therapeutics LimitedUpdated: Jan 30, 2026Locations: 2
Eligibility criteria
The subject is between 18 and 55 years of age (both inclusive) at the date of sc... [+7]
Presence of any clinically significant illness, such as cardiovascular, neurolog... [+7]